Muscle Growth$60–$115

Tesamorelin: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 10 sources cited

Overview

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus that enhances receptor binding and enzymatic stability. It is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it one of the few peptides with specific FDA approval for a body composition indication. Tesamorelin is the most potent GHRH analog in clinical use and has shown remarkable specificity for visceral fat reduction.

Mechanism of Action

Tesamorelin binds to the GHRH receptor (GHRH-R) on pituitary somatotroph cells with higher affinity than native GHRH or sermorelin, due to the trans-3-hexenoic acid (THA) modification that protects against DPP-IV degradation and enhances receptor interaction. Upon GHRH-R activation, the same adenylyl cyclase → cAMP → PKA cascade stimulates GH synthesis and release. However, tesamorelin produces a more robust and sustained GH pulse compared to sermorelin, typically elevating IGF-1 by 40–100% from baseline. The resulting GH/IGF-1 elevation drives several body composition effects: increased lipolysis in visceral adipose tissue (which has high GH receptor density), reduced lipogenesis, increased lean mass through enhanced protein synthesis, and improved hepatic fat metabolism. Tesamorelin preserves pulsatile GH release and hypothalamic-pituitary feedback, unlike exogenous GH. Notably, tesamorelin has shown specific efficacy against visceral adipose tissue (VAT) — the metabolically dangerous deep abdominal fat associated with cardiovascular disease, insulin resistance, and NAFLD. In clinical trials, it reduced VAT by 15–18% while subcutaneous fat was less affected, suggesting a preferential mechanism related to the higher GH receptor expression and lipolytic sensitivity of visceral adipocytes. Additionally, tesamorelin has demonstrated cognitive benefits — it improved verbal memory and executive function in cognitively normal older adults, possibly through IGF-1-mediated neurogenesis and synaptic plasticity in the hippocampus.

Tesamorelin Benefits: What the Research Shows

  • Phase III trials for HIV lipodystrophy (pooled n=806) demonstrated a 15.4% reduction in visceral adipose tissue measured by CT at 26 weeks vs. placebo
  • Stanley et al. (2019, Lancet HIV) showed tesamorelin reduced liver fat by 37% over 12 months in HIV patients with hepatic steatosis
  • Cognition study (Baker et al., 2012, Archives of Neurology) demonstrated tesamorelin improved executive function in adults aged 55–87, both healthy and with mild cognitive impairment
  • IGF-1 levels increased by about 81% from baseline in the pivotal trial, and at week 26 the label reports 47% of treated patients above an IGF-1 standard deviation score of 2
  • Glucose parameters did not change meaningfully in the HIV lipodystrophy trials, though the label reports more treated patients reaching an HbA1c of 6.5% or higher than placebo
  • A 12-month trial in non-HIV abdominally obese adults with reduced GH secretion showed reduced visceral fat, triglycerides and carotid intima-media thickness
  • Long-term extension studies showed sustained visceral fat reduction with continued use, with fat regain upon discontinuation

Tesamorelin Dosage

  • FDA-approved dose: 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR) subcutaneous injection once daily
  • Anti-aging/body composition protocols: 1–2 mg subcutaneous injection daily, typically at bedtime
  • Some protocols use 1 mg daily for a more conservative approach with fewer side effects
  • Inject on an empty stomach — food (especially fats/carbs) suppresses the GH response
  • Bedtime administration synergizes with the natural nocturnal GH pulse
  • Avoid eating within 60–90 minutes of injection
  • Cycle: 3–6 months on; some clinics prescribe continuously with periodic IGF-1 monitoring
  • Often combined with a GHRP (ipamorelin) for synergistic GH release
  • Monitor IGF-1 levels every 3 months and adjust dose to maintain upper-normal range
Tesamorelin dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Tesamorelin Side Effects & Safety

Known Side Effects

  • Injection site reactions (erythema, pruritus, pain) in approximately 17% of patients in the label's trials, vs 6% on placebo
  • Arthralgia (joint pain) and myalgia — related to GH/IGF-1 elevation, reported in 13% and 6% of patients in the label's trials
  • Peripheral edema and water retention, especially in the first few weeks
  • Paresthesias (tingling, numbness in extremities) — signs of fluid retention and nerve compression
  • Headache, though the label does not list it among reactions more frequent than placebo
  • Transient hyperglycemia — GH is a counter-regulatory hormone; monitor fasting glucose and HbA1c
  • Carpal tunnel-like symptoms at higher doses due to fluid retention
  • Hypersensitivity reactions (rare)

Safety Profile

Tesamorelin has a well-established safety profile from FDA-approval studies and post-marketing surveillance. The most significant safety consideration is its effect on glucose metabolism — GH elevates blood glucose, and tesamorelin may worsen glycemic control in patients with diabetes or pre-diabetes. In the label's trials, 5% of treated patients vs 1% on placebo had an HbA1c of 6.5% or higher at week 26, with an odds ratio of 3.3 for developing diabetes. However, paradoxically, the reduction in visceral fat often improves insulin sensitivity over time, partially offsetting the acute hyperglycemic effect. Tesamorelin is contraindicated in patients with active malignancy (GH/IGF-1 may promote tumor growth), disruption of the hypothalamic-pituitary axis (e.g., from surgery or radiation), and hypersensitivity to tesamorelin or mannitol. Pregnancy is a labeled contraindication, and animal studies showed hydrocephaly in offspring. IGF-1 levels should be monitored regularly and doses adjusted to avoid supraphysiological elevation. Long-term safety in non-HIV populations is less established but appears favorable based on available data.

What to Expect

Week 1–2: Improved sleep quality and increased dream vividness are typically the first effects noticed. Subtle improvement in energy levels. Minor water retention and joint stiffness may occur as GH levels rise. Week 2–4: Sleep continues to improve. Recovery from exercise is noticeably better. IGF-1 levels begin rising significantly. Mild fluid retention peaks and begins stabilizing. Week 4–8: Body composition changes begin — clothes may fit differently around the midsection. Skin quality starts improving (increased hydration and elasticity). Fat loss becomes measurable, particularly in the abdominal region. Week 8–16: Significant visceral fat reduction (10–15%). Lean mass improvements become apparent. Cognitive benefits may emerge — improved focus, verbal fluency, and mental clarity. Metabolic markers (triglycerides, liver enzymes) begin improving. Week 16–26: Full effects manifest with 15–18% visceral fat reduction. Visible abdominal slimming. Improved exercise capacity. Hair and nail growth may accelerate. Benefits continue as long as treatment continues; fat regain occurs gradually after discontinuation.

Common Stacks

Storage & Handling

Egrifta (commercial product): Store unreconstituted vials at room temperature, 20–25°C (68–77°F). Protect from light. Keep in the original box. Reconstitute with the provided sterile water; Egrifta SV is used immediately, and Egrifta WR is kept at room temperature and discarded 7 days after mixing. Compounded tesamorelin: Store lyophilized powder at -20°C for long-term storage or 2–8°C for up to 12 months. Reconstitute with bacteriostatic water; store at 2–8°C and use within 21–28 days. Do not freeze reconstituted solution.

Pricing & Available Variants

$60 – $115price range
10mg20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. EGRIFTA WR (tesamorelin) for injection: full prescribing information. Theratechnologies, via DailyMed. 2025.
  2. EGRIFTA SV (tesamorelin) for injection: full prescribing information. Theratechnologies, via DailyMed. 2024.
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.
  4. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010.
  5. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008.
  6. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019.
  7. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014.
  8. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012.
  9. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012.
  10. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011.

Related Peptides

Track Tesamorelin in Your Protocol

Log your Tesamorelin doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free